Stem definition | Drug id | CAS RN |
---|---|---|
local anaesthetics | 3016 | 99-43-4 |
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
March 9, 2020 | FDA | BAUSCH |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Toxic anterior segment syndrome | 167.69 | 114.70 | 21 | 84 | 1750 | 63487167 |
None
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Toxic anterior segment syndrome | 176.24 | 84.76 | 24 | 153 | 2740 | 79741471 |
Aqueous fibrin | 126.02 | 84.76 | 13 | 164 | 125 | 79744086 |
None
Source | Code | Description |
---|---|---|
ATC | D04AB03 | DERMATOLOGICALS ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. Anesthetics for topical use |
ATC | S01HA02 | SENSORY ORGANS OPHTHALMOLOGICALS LOCAL ANESTHETICS Local anesthetics |
MeSH PA | D000777 | Anesthetics |
MeSH PA | D000779 | Anesthetics, Local |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D002492 | Central Nervous System Depressants |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D018689 | Sensory System Agents |
CHEBI has role | CHEBI:36333 | local anesthetics |
CHEBI has role | CHEBI:48425 | topical anesthetic |
CHEBI has role | CHEBI:88188 | allergenic drug |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Topical local anesthetic to eye | indication | 231346001 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.8 | Basic |
pKa2 | 2.87 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
0.4%;0.3% | FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE | BAUSCH LOMB IRELAND | N211039 | March 9, 2020 | RX | SOLUTION/DROPS | OPHTHALMIC | 10293047 | Nov. 15, 2037 | OCULAR EXAMINATION, INTRAOCULAR PRESSURE MEASUREMENT, OR REMOVAL OF FOREIGN BODIES OR SUTURES, IN ADULT AND PEDIATRIC PATIENTS REQUIRING A DISCLOSING AGENT IN COMBINATION WITH A TOPICAL OPHTHALMIC ANESTHETIC |
0.4%;0.3% | FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE | BAUSCH LOMB IRELAND | N211039 | March 9, 2020 | RX | SOLUTION/DROPS | OPHTHALMIC | 10632197 | Nov. 15, 2037 | OCULAR EXAMINATION, INTRAOCULAR PRESSURE MEASUREMENT, OR REMOVAL OF FOREIGN BODIES OR SUTURES, IN ADULT AND PEDIATRIC PATIENTS REQUIRING A DISCLOSING AGENT IN COMBINATION WITH A TOPICAL OPHTHALMIC ANESTHETIC |
0.4%;0.3% | FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE | BAUSCH LOMB IRELAND | N211039 | March 9, 2020 | RX | SOLUTION/DROPS | OPHTHALMIC | 10842872 | Nov. 15, 2037 | PROCEDURES IN ADULT AND PEDIATRIC PATIENTS REQUIRING A DISCLOSING AGENT IN COMBINATION WITH A TOPICAL OPHTHALMIC ANESTHETIC. |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Sodium channel protein type 10 subunit alpha | Ion channel | BLOCKER | DRUGBANK | CHEMBL | |||||
Sodium channel alpha subunits; brain (Types I, II, III) | Ion channel | BLOCKER | IC50 | 5.54 | CHEMBL | CHEMBL |
ID | Source |
---|---|
4019627 | VUID |
N0000179047 | NUI |
D08319 | KEGG_DRUG |
5987-82-6 | SECONDARY_CAS_RN |
4018751 | VANDF |
4019627 | VANDF |
CHEBI:309594 | CHEBI |
CHEMBL1200 | ChEMBL_ID |
CHEMBL1200654 | ChEMBL_ID |
C005298 | MESH_SUPPLEMENTAL_RECORD_UI |
7123 | IUPHAR_LIGAND_ID |
DB00892 | DRUGBANK_ID |
18889 | RXNORM |
4253 | MMSL |
001355 | NDDF |
004569 | NDDF |
370315001 | SNOMEDCT_US |
387063004 | SNOMEDCT_US |
52140009 | SNOMEDCT_US |
C0053114 | UMLSCUI |
275 | INN_ID |
4633 | PUBCHEM_CID |
AXQ0JYM303 | UNII |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
FLURESS | HUMAN PRESCRIPTION DRUG LABEL | 2 | 17478-640 | SOLUTION/ DROPS | 4 mg | OPHTHALMIC | unapproved drug other | 15 sections |
Fluorescein Sodium and Benoxinate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 24208-734 | SOLUTION/ DROPS | 4.40 mg | OPHTHALMIC | NDA | 21 sections |
Fluorescein Sodium and Benoxinate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 24208-734 | SOLUTION/ DROPS | 4.40 mg | OPHTHALMIC | NDA | 21 sections |
Flurox | HUMAN PRESCRIPTION DRUG LABEL | 2 | 54799-508 | SOLUTION | 4 mg | OPHTHALMIC | unapproved drug other | 12 sections |
ALTAFLUOR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 59390-218 | SOLUTION | 4 mg | OPHTHALMIC | NDA | 21 sections |
ALTAFLUOR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 59390-218 | SOLUTION | 4 mg | OPHTHALMIC | NDA | 21 sections |
Fluorescein Sodium and Benoxinate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 68682-732 | SOLUTION/ DROPS | 4.40 mg | OPHTHALMIC | NDA authorized generic | 21 sections |
Fluorescein Sodium and Benoxinate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 82260-734 | SOLUTION/ DROPS | 4.40 mg | OPHTHALMIC | NDA authorized generic | 21 sections |